|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
251,929 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
19 |
27 |
56 |
End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
officerTitle |
|
2006-02-01 |
4 |
AB |
$11.62 |
$17,500 |
D/D |
1,500 |
14,000 |
|
- |
|
Sager Erich |
officerTitle |
|
2006-01-27 |
4 |
AS |
$12.20 |
$30,500 |
D/D |
(2,500) |
3,309 |
|
- |
|
Sager Erich |
officerTitle |
|
2006-01-27 |
4 |
OE |
$7.00 |
$17,500 |
D/D |
2,500 |
5,809 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2006-01-04 |
4 |
OE |
$4.00 |
$200,000 |
D/D |
50,000 |
88,144 |
|
- |
|
Bienaime Jean Jacques |
officerTitle |
|
2006-01-03 |
4 |
B |
$10.76 |
$16,190 |
D/D |
1,500 |
12,500 |
2.81 |
- |
|
Bienaime Jean Jacques |
officerTitle |
|
2005-12-12 |
4 |
B |
$10.21 |
$10,208 |
D/D |
1,000 |
11,000 |
2.81 |
- |
|
Sager Erich |
officerTitle |
|
2005-12-05 |
4 |
AS |
$10.70 |
$80,261 |
D/D |
(7,500) |
3,309 |
|
- |
|
Sager Erich |
officerTitle |
|
2005-12-01 |
4/A |
S |
$10.42 |
$234,450 |
D/D |
(22,500) |
3,309 |
|
- |
|
Bienaime Jean Jacques |
officerTitle |
|
2005-12-01 |
4 |
AB |
$9.89 |
$14,916 |
D/D |
1,500 |
10,000 |
|
- |
|
Sager Erich |
officerTitle |
|
2005-12-01 |
4 |
S |
$10.42 |
$234,450 |
D/D |
(22,500) |
0 |
|
- |
|
Starr Christopher M |
officerTitle |
|
2005-12-01 |
4 |
AS |
$10.00 |
$105,710 |
D/D |
(10,571) |
295,176 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2005-11-21 |
4 |
AS |
$10.00 |
$300,000 |
D/D |
(30,000) |
10,000 |
|
- |
|
Starr Christopher M |
SVP, Chief Scientific Officer |
|
2005-11-21 |
4 |
AS |
$10.00 |
$105,710 |
D/D |
(10,571) |
300,176 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2005-11-01 |
4 |
AB |
$8.36 |
$12,550 |
D/D |
1,500 |
8,500 |
|
- |
|
Kakkis Emil D |
officerTitle |
|
2005-10-31 |
4 |
A |
$3.43 |
$8,832 |
D/D |
2,572 |
29,574 |
|
- |
|
Baffi Robert |
officerTitle |
|
2005-10-31 |
4 |
A |
$3.43 |
$12,500 |
D/D |
3,640 |
22,749 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2005-10-12 |
4/A |
AB |
$7.00 |
$3,500 |
D/D |
500 |
7,000 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2005-10-12 |
4 |
AB |
$7.00 |
$3,500 |
D/D |
500 |
6,500 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2005-10-06 |
4 |
AB |
$8.00 |
$4,000 |
D/D |
500 |
6,500 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2005-10-03 |
4 |
AB |
$8.51 |
$12,765 |
D/D |
1,500 |
6,000 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2005-09-01 |
4 |
AB |
$8.58 |
$38,588 |
D/D |
4,500 |
4,500 |
|
- |
|
Klein Joseph III |
Director |
|
2005-06-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
12,000 |
|
- |
|
Drapeau Louis |
Chief Executive Officer |
|
2005-05-02 |
4 |
A |
$3.43 |
$13,750 |
D/D |
4,004 |
14,934 |
|
- |
|
Baffi Robert |
SVP, Technical Operations |
|
2005-05-02 |
4 |
A |
$3.43 |
$2,115 |
D/D |
616 |
19,109 |
|
- |
|
Kakkis Emil D |
SVP, Business Operations |
|
2005-05-02 |
4 |
A |
$3.43 |
$6,758 |
D/D |
1,968 |
27,002 |
|
- |
|
1213 Records found
|
|
Page 48 of 49 |
|
|